Clinical and tumor features of patients with immune checkpoint inhibitor-related neurological disorders and anti-Yo antibodies.

ABSTRACT:

Background

Anti-Yo antibodies, which target the onconeural antigen cerebellar degeneration-related 2-like (CDR2L), have been only sporadically reported in patients with post-immune checkpoint inhibitor (post-ICI) neurological syndromes.

Objectives

To analyze the clinical and tumor features of patients with post-ICI anti-Yo neurological syndromes identified in a national reference center.

Design

Retrospective observational study.

Methods

All patients with post-ICI neurological syndromes and anti-Yo antibody positivity confirmed in a national reference center (2019-2024) were included. Comparative genomic hybridization array, immunohistochemistry against CDR2L, and analysis of Yo immunoreactivity using biotinylated anti-Yo sera were performed on the available tum

SUBMITTER: Farina A 

PROVIDER: S-EPMC12572610 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature